Protocol for a double-blind placebo-controlled trial to evaluate the efficacy of probiotics in reducing antibiotics for infection in care home residents: the Probiotics to Reduce Infections iN CarE home reSidentS (PRINCESS) trial
Open Access
- 20 June 2019
- Vol. 9 (6), e027513
- https://doi.org/10.1136/bmjopen-2018-027513
Abstract
Introduction Care home residents are at increased risk of infections and antibiotic prescription. Reduced antibiotic use from fewer infections would improve quality of life. The Probiotics to Reduce Infections iN CarE home reSidentS (PRINCESS) trial aims to determine the efficacy and investigate mechanisms of daily probiotics on antibiotic use and incidence of infections in care home residents. Methods and analysis PRINCESS is a double-blind, individually randomised, placebo-controlled trial that will assess the effect of a daily oral probiotic combination of Lactobacillus rhamnosus, GG (LGG) and Bifidobacterium animalis subsp. lactis, BB-12 (BB-12) on cumulative antibiotic administration days (CAADs) (primary outcome) for infection in up to 330 care home residents aged ≥65 years over up to 12 months. Secondary outcomes include: Infection: Total number of days of antibiotic administration for each infection type (respiratory tract infection, urinary tract infection, gastrointestinal infection, unexplained fever and other); number, site, duration of infection; estimation of incidence and duration of diarrhoea and antibiotic-associated diarrhoea; Stool microbiology: Clostridium difficile infection; Gram-negative Enterobacteriaceae and vancomycin-resistant enterococci; LGG and BB-12. Oral microbiology: Candida spp. Health and well-being: Self and/or proxy health-related quality of life EQ5D (5 L); self-and/or proxy-reported ICEpop CAPability measure for older people. Hospitalisations: number and duration of all-cause hospital stays. Mortality: deaths. Mechanistic immunology outcomes: influenza vaccine efficacy (haemagglutination inhibition assay and antibody titres); full blood count and immune cell phenotypes, plasma cytokines and chemokines; cytokine and chemokine response in whole blood stimulated ex vivo by toll-like receptor 2 and 4 agonists; monocyte and neutrophil phagocytosis of Escherichia coli; serum vitamin D. Ethics and dissemination Ethics approval is from the Wales Research Ethics Committee 3. Findings will be disseminated through peer-reviewed journals and conferences; results will be of interest to patient and policy stakeholders. Trial registration number ISRCTN16392920; Pre-results.Keywords
Funding Information
- Efficacy and Mechanism Evaluation Programme
This publication has 31 references indexed in Scilit:
- Modulation of vaccine response by concomitant probiotic administrationBritish Journal of Clinical Pharmacology, 2013
- A new taxonomy for describing and defining adherence to medicationsBritish Journal of Clinical Pharmacology, 2012
- Does taking probiotics routinely with antibiotics prevent antibiotic associated diarrhoea?BMJ, 2012
- Gut microbiota, probiotics, and vitamin D: Interrelated exposures influencing allergy, asthma, and obesity?Journal of Allergy and Clinical Immunology, 2011
- Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trialEuropean Journal of Clinical Nutrition, 2011
- Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysisBMJ, 2010
- Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled studyBritish Journal of Nutrition, 2008
- The Safety of ProbioticsClinical Infectious Diseases, 2008
- Causal Inference with Generalized Structural Mean ModelsJournal of the Royal Statistical Society Series B: Statistical Methodology, 2003
- Multiple Antibiotic–Resistant Bacteria in Long‐Term‐Care Facilities: An Emerging Problem in the Practice of Infectious DiseasesClinical Infectious Diseases, 2000